OA04.01 What Is the Cost of a Strong Evidence for the Treatment of Advanced Non-Small Cell Lung Cancer?

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.251
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Targeted Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2005English

Cost Effectiveness of Treatment With New Agents in Advanced Non-Small-Cell Lung Cancer

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2012English

Afatinib Treatment in Advanced Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2011English

Algorithm for the Treatment of Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer: An Evidence-Based Overview

Current Oncology
Oncology
2018English

What Phase III Trials Are Needed to Improve the Treatment of Advanced Non-Small-Cell Lung Cancer?

Nature Clinical Practice Oncology
2005English

Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Single‐Agent Paclitaxel in the Treatment of Advanced Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
1999English

Gefitinib for the Treatment of Non-Small-Cell Lung Cancer

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2010English

Developments in the Management of Advanced Non Small Cell Lung Cancer

Journal of Cancer Therapy
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy